Mark Yondola
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$15.8MFederal grants as PI18 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
18 awards · $15.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Mar 23, 2022 | NIH | SBIR Phase II An RSV Prefusion F Vaccine that Overcomes Immunosenescence | $985K | Calder Biosciences Inc. |
| Mar 4, 2021 | NIH | SBIR Phase II An RSV Prefusion F Vaccine that Overcomes Immunosenescence | $989K | Calder Biosciences Inc. |
| Feb 15, 2020 | NIH | SBIR Phase II An RSV Prefusion F Vaccine that Overcomes Immunosenescence | $2.9M | Calder Biosciences Inc. |
| Feb 12, 2020 | NIH | SBIR Phase II An RSV Prefusion F Vaccine that Overcomes Immunosenescence | $940K | Calder Biosciences Inc. |
| Nov 27, 2019 | NIH | SBIR Phase II A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | $888K | Calder Biosciences Inc. |
| Aug 14, 2019 | NIH | SBIR Phase II A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | $375K | Calder Biosciences Inc. |
| Jul 12, 2019 | NIH | SBIR Phase II Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine | $99K | Calder Biosciences Inc. |
| Jun 21, 2019 | NIH | SBIR Phase I An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | $300K | Calder Biosciences Inc. |
| May 10, 2019 | NIH | SBIR Phase II An RSV Prefusion F Vaccine that Overcomes Immunosenescence | $300K | Calder Biosciences Inc. |
| Nov 9, 2018 | NIH | SBIR Phase II A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | $612K | AVATAR MEDICAL, LLC |
| Jul 5, 2018 | NIH | SBIR Phase I An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | $300K | Calder Biosciences Inc. |
| Jul 5, 2018 | NIH | SBIR Phase I An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | $600K | Calder Biosciences Inc. |
| Jan 10, 2018 | NIH | SBIR Phase II A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | $2.9M | Calder Biosciences Inc. |
| Jan 9, 2018 | NIH | SBIR Phase II A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | $987K | Calder Biosciences Inc. |
| Jun 16, 2017 | NIH | SBIR Phase II Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine | $651K | Calder Biosciences Inc. |
| Jul 2, 2016 | NIH | SBIR Phase II Dityrosine Locked Prefusion F Protein A Path To A Protective RSV Vaccine | $1.5M | AVATAR MEDICAL, LLC |
| Apr 28, 2015 | NIH | SBIR Phase I Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine | $297K | AVATAR MEDICAL, LLC |
| Feb 15, 2015 | NIH | SBIR Phase I A Universal Flu Vaccine Based on Conformationally Locked Soluble Headless HA | $225K | AVATAR MEDICAL, LLC |
Peer ranks
Federal funding#14
Awards as PI#24
Patents#273
Companies
- AVATAR MEDICAL, LLCLinked by awards · Biotech
- Calder Biosciences Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.